According to Quantum Leap Healthcare Collaborative (QLHC), a sponsor of the I-SPY COVID trial, interim analysis of data from a study of Genentech’s Pulmozyme dornase alfa inhalation solution for the treatment of severe COVID-19 found that Pulmozyme therapy “is unlikely to achieve statistically significant improvement in efficacy,” and the Pulmozyme arm of the trial has therefore been terminated. The I-SPY COVID trial, which is run by QLHC and supported by the US government and several pharmaceutical companies, including Genentech, screens multiple drugs for efficacy in reducing mortality and time to recovery in severe COVID-19.
The Pulmozyme arm of the trial enrolled 125 patients and evaluated Pulmozyme plus standard of care versus standard of care alone. Although the 37 patients who received Pulmozyme experienced no significant adverse events, there was no statistically significant difference compared to standard of care alone and patients who got Pulmozyme actually had slower recovery times, QLHC said.
Jon Koff of the Yale School of Medicine, who led the Pulmozyme arm of the trial commented, “We demonstrated that Pulmozyme could be safely administered to critically ill patients with COVID-19. Unfortunately, it did not demonstrate a large improvement in the time to recovery, nor in the reduction in mortality.”
Read the Quantum Leap Healthcare Collaborative press release.
